Letrozole

• Description :

  Letrozole (CGS 20267) is a potent, selective, reversible and orally active non-steroidal inhibitor of aromatase, with an IC50 of 11.5 nM. Letrozole selective inhibits estrogen biosynthesis, and can be used for the research of breast cancer[1][2][3].

• CAS Number :

  [112809-51-5]

• Product Name Alternative :

  CGS 20267

• UNSPSC :

  12352005

• Hazard Statement :

  H361, H373

• Target :

  Autophagy; Cytochrome P450

• Type :

  Natural Products

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Letrozole.html

• Concentration :

  10mM

• Purity :

  99.95

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  N#CC1=CC=C(C(N2C=NC=N2)C3=CC=C(C#N)C=C3)C=C1

• Molecular Formula :

  C17H11N5

• Molecular Weight :

  285.30

• Precautions :

  H361, H373

• References & Citations :

  [1]Bhatnagar AS, et, al. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol. 1990 Dec 20;37 (6) :1021-7.|[2]Mitropoulou TN, et, al. Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer. 2003 Mar 20;104 (2) :155-60.|[3]Schieweck K, et, al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors. J Steroid Biochem Mol Biol. 1993 Mar;44 (4-6) :633-6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched

• Isoform :

  Aromatase/CYP19A1